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Differentiation and dedifferentiation of vascular smooth muscle cells (VSMCs) are essential
processes of vascular development. VSMC have biosynthetic, proliferative, and contractile
roles in the vessel wall. Alterations in the differentiated state of the VSMC play a critical
role in the pathogenesis of a variety of cardiovascular diseases, including atherosclerosis,
hypertension, and vascular stenosis. This review provides an overview of the current state
of knowledge of molecular mechanisms involved in the control of VSMC proliferation, with
particular focus on mitochondrial metabolism. Mitochondrial activity can be controlled by
regulating mitochondrial dynamics, i.e., mitochondrial fusion and fission, and by regulating
mitochondrial calcium handling through the interaction with the endoplasmic reticulum
(ER). Alterations in both VSMC proliferation and mitochondrial function can be triggered
by dysregulation of mitofusin-2, a small GTPase associated with mitochondrial fusion
and mitochondrial–ER interaction. Several lines of evidence highlight the relevance of
mitochondrial metabolism in the control of VSMC proliferation, indicating a new area to
be explored in the treatment of vascular diseases.
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INTRODUCTION
Vascular smooth muscle cells (VSMCs) are the main compo-
nent of the artery’s medial layer. These cells undergo contraction
and thereby regulate blood vessel tone and consequently blood
flow and pressure. VSMC contraction depends on the inter-
action between smooth muscle α-actin, β-myosin heavy chain,
h-caldesmon, and calponin (Rzucidlo et al., 2007; Cecchettini
et al., 2011). VSMCs also possess important secretory properties
that ensure synthesis and repair of extracellular matrix compo-
nents and regulate the structure of the vascular wall (Cecchettini
et al., 2011). Normal VSMCs are not terminally differentiated
cells with very low rates of proliferation and secretion (Rzucidlo
et al., 2007; Cecchettini et al., 2011). Changes in the VSMC phe-
notype have been extensively described in the development and
progression of atherosclerosis, hypertension, and neointimal for-
mation (Campbell and Campbell, 1985; Rzucidlo et al., 2007;
Cecchettini et al., 2011). This phenotypic switching includes
altered expression of contractile proteins, increased matrix pro-
duction, expression of inflammatory cytokines, and production
of proteases (Campbell and Campbell, 1985). The capacity for
contraction, proliferation, migration, and secretion in VSMCs
are affected by a wide range of factors, including mechanical
forces, contractile agonists such as angiotensin II, extracellu-
lar matrix, reactive oxygen species (ROS), endothelial–VSMC
interactions, platelet derived growth factor (PDGF), transform-
ing growth factor-β1, hypoxia, and many other growth factors
(Campbell and Campbell, 1985; Cecchettini et al., 2011). As a
result, VSMCs constitute basic structural and functional elements
in the artery wall and their malfunction leads to vascular disease.
Recently, VSMC mitochondrial metabolism has been raised as
part of novel mechanisms involved in the complex regulation of
the VSMC phenotype, especially involving VSMC proliferation.
In this review, we will examine the evidence that supports this
hypothesis.
REGULATION OF MITOCHONDRIAL METABOLISM
Mitochondria have been considered the energy powerhouses in all
eukaryotic cells (Scheffler, 2001). They are particularly abundant
in muscle cells and most of the energy needed for muscle contrac-
tion is provided by mitochondrial metabolism (Kuznetsov et al.,
2009). Mitochondria has four compartments: the outer mito-
chondrial membrane (OMM), the intermembrane space (IMS),
the inner mitochondrial membrane (IMM), and the mitochon-
drial matrix (Scheffler, 2001). The IMM is particularly dense and
enriched in a variety of membrane proteins, including the mito-
chondrial respiratory complexes and the ATP synthase (Scheffler,
2001). The driving energy for ATP synthesis comes from the gen-
eration of a protonmotive force by the electron transport chain in
the IMM. This gradient of concentration and charge constitutes
the intermembrane mitochondrial potential (ψm) and is main-
tained by the oxidation of reduced substrates generated mainly by
the oxidation of metabolites in the Krebs cycle and β-oxidation of
fatty acids (Scheffler, 2001; Kuzmicic et al., 2011).
VSMCs exhibit unusually high rates of glucose metabolization
and lactate production under normal, well-oxygenated condi-
tions (Butler and Siegman, 1985). Under resting conditions, the
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rate of oxygen consumption and lactate production are often
almost equal on a molar basis, resulting in approximately 30%
of the ATP supply coming frommitochondria, but at least 90% of
the flux through glycolysis resulting in lactate production (Paul,
1983). In spite of the low contribution of mitochondria to the
VSMC bioenergetics, mitochondrial dysfunction, and particu-
larly mitochondrial DNA damage, has recently been associated to
atherosclerosis (Yu and Bennett, 2014). Recent studies show that
during VSMC phenotypic switching, mitochondria decreases glu-
cose oxidation and increases fatty acid oxidation (Salabei andHill,
2013). This suggests that VSMC redirects the use of glucose or
its metabolites to pathways that support the biosynthesis of DNA
and other molecules required for VSMC proliferation. This pro-
cess is similar to theWarburg effect present in cancer cells (Vander
Heiden et al., 2009).
Mitochondria were originally thought as discrete, isolated
entities scattered in the cytoplasm. However, this vision has
changed to a dynamic network model in which mitochondria
are in close communication with the endoplasmic reticulum (ER)
and the entire morphology of the organelle is controlled by coor-
dinated fusion and fission events. The appropriate balance of
these processes is essential to maintain mitochondrial stability
and function (Kuzmicic et al., 2011; Parra et al., 2011).
MITOCHONDRIAL DYNAMICS AND METABOLISM
Mitochondrial fusion stimulates the assembly of individual mito-
chondria that combine their membranes (Figure 1A). This pro-
cess is controlled by mitofusins (Mfn) 1 and 2 and OPA-1,
a member of the dynamin family of mechanoenzymes (Parra
et al., 2011). Mfn-1 and Mfn-2 are two evolutionarily con-
served GTPase proteins that attach to the OMM via a bipartite,
N-terminal transmembrane domain with their C-terminal coiled-
coil region inserting into the cytosol. During mitochondrial
fusion, Mfn-1 and Mfn-2 form hetero-oligomers that hydrolyze
GTP and promote rearrangement of mitochondrial membranes
(Carlucci et al., 2008). Mitochondrial fusion is a two-step process,
where the IMM and OMM fuse by separate events (Malka et al.,
2005; Zorzano et al., 2010), which can be explained by the mito-
chondrial sub-localization of Mfn-1, Mfn-2, and OPA-1. Mfn-1
and Mfn-2 are located in the OMM, where they can regulate the
OMM fusion, and OPA-1 is located in the IMM, where it can
regulate the IMM fusion (Zorzano et al., 2010).Mitochondrial fis-
sion entails fragmentation of tubular interconnected mitochon-
dria into several smaller individual organelles (Figure 1B). The
OMM protein FIS-1 and the GTPase dynamin related protein-1
(DRP-1) are the main elements of the mitochondrial fission
machinery (Parra et al., 2011). Down regulation or inhibition of
FIGURE 1 | Mitochondrial dynamics. (A) Mitochondrial fusion. This is a
two-step process which involves three different proteins: mitofusin-1
and 2 (Mfn-1 and Mfn-2) and optic atrophy protein-1 (OPA-1). Mfn-1
and Mfn-2 are transmembrane GTPases embedded in the outer
mitochondrial membrane (OMM). The C-terminal coiled-coil region of
Mfn-1 and Mfn-2 mediates tethering between mitochondria through
homo- or heterotypic complexes formed between adjacent mitochondria.
This interaction mediates OMM fusion. OPA-1 is a dynamin-related
protein localized in the inner mitochondrial membrane (IMM), facing the
intermembrane space. OPA-1 participates in the attachment and fusion
of IMM. Mitochondrial fusion is associated with an increase in the
mitochondrial potential (ψm), oxygen consumption, and ATP
production. (B) Mitochondrial fission. In this process participates
dynamin-related protein-1 (DRP-1) and fission protein-1 (FIS-1). DRP-1 is
a large GTPase found soluble in the cytosol of cells from where it
shuttles onto and off mitochondria. DRP-1 assembles into spirals at
division sites around the OMM to drive the fission process. In yeast,
the mechanism for recruitment of DRP-1 to the mitochondria requires
FIS-1, a tetratricopeptide domain protein anchored into and evenly
coating the entire OMM. DRP-1 activity is inhibited by a protein kinase
A (PKA) phosphorylation. Mitochondrial fission is associated with a
ψm, oxygen consumption, and ATP production decrease.
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DRP-1 or FIS-1 severely inhibits mitochondrial fission and gen-
erates an extended mitochondrial membranous network (James
et al., 2003; Cerveny et al., 2007). Furthermore, DRP-1 knock-
out mice show that DRP-1 not only affects mitochondrial fission
but also affects cell proliferation generating non-viable embryos
(Wakabayashi et al., 2009). Ishihara et al. also showed that neu-
ral specific DRP-1 knock-out mice dies shortly after birth as a
result of brain hypoplasia (Ishihara et al., 2009). This process is
accompanied with an imbalance between mitochondrial fusion
and fission, and deregulation of normal cytochrome c release
and caspase activation during apoptosis (Ishihara et al., 2009).
DRP-1 possesses an N-terminal GTPase domain and a C-terminal
GTPase effector domain, which is involved in intramolecular and
intermolecular interactions and modulates the GTPase activity.
Cytosolic DRP-1 is recruited to the mitochondrial surface into
the fission foci by adaptor proteins, including FIS-1 (Hoppins,
2014; Mishra and Chan, 2014; Nasrallah and Horvath, 2014).
FIS-1 is an integral protein of the OMM and contains a cytosolic
hydrophobic tetratricopeptide repeat (TPR). The TPR is thought
to interact with DRP-1 (Carlucci et al., 2008; Hoppins, 2014).
At fission sites, DRP-1 forms spiral chains around membrane
constriction sites. GTP hydrolysis provides energy to generate
the mechanical force required for fission (Carlucci et al., 2008).
There are other adaptors that can recruit DRP-1 to the mito-
chondria membrane, i.e., the mitochondrial fission factor (MFF)
and mitochondrial dynamic proteins 49 and 51 kDa (MiD49 and
MiD51). These proteins can triggermitochondrial fission through
a FIS-1-independent process (Palmer et al., 2013).
Mitochondrial fission occurs preferentially at ER contact sites.
Inverted formin 2 (INF2), a protein involved in actin polymer-
ization and depolymerization located at the ER, has a direct
effect on mitochondrial fission. INF2 facilitates both the interac-
tion of DRP-1 with mitochondria and the fission process in an
actin-dependent manner. Actin filaments appeared to accumu-
late between mitochondria and INF2-enriched ER membranes at
constriction sites. Thus, INF2-induced actin filaments may drive
initial mitochondrial constriction, which allows DRP-1-driven
secondary constriction (Korobova et al., 2013).
Several lines of evidence have shown that the machinery that
governs mitochondrial dynamics also participates in the tem-
poral regulation of metabolism and cell death (Kuzmicic et al.,
2011; Parra et al., 2011). The dynamic shifts in morphology coin-
cide with a number of physiological events, such as transitions
between different respiratory states and cristae remodeling during
apoptosis (Parra et al., 2011). Aberrations in cristae morphology
are accompanied by changes in metabolism (Parra et al., 2011;
Nasrallah and Horvath, 2014), and together with the down regu-
lation of OPA-1 or Mfn, trigger alterations of the IMM structures
which leads to fragmented mitochondria with greatly reduced
oxygen consumption and electrochemical potential (Chen and
Chan, 2005). Mitochondria also contribute to glycolysis regula-
tion; in cases of increased ATP demand, mitochondrial pyruvate
dehydrogenase activity is up regulated, increasing glycolytic con-
tribution to cell metabolism (Sharma et al., 2005). The first
evidence of a relationship between mitochondrial morphology
and function derived from studies of fusion inhibition, which
leads to a reduced oxygen consumption and loss of ψmt and
mitochondrial DNA (Chen et al., 2003; Chen and Chan, 2005).
Silencing of Mfn-2 substantially impairs metabolic parameters
(Pich et al., 2005), and animal models of obesity show a marked
reduction of Mfn-2 levels in muscle cells. Similarly, decreased
OPA-1 levels lead to mitochondrial fragmentation, decreased
oxygen consumption, and ψmt dissipation, and have been
implicated in the pathogenesis of neurodegenerative diseases and
heart failure (Bossy-Wetzel et al., 2003; Chen et al., 2009). Taken
together, these results reinforce the concept that mitochondrial
plasticity is critical for cell metabolism adaptation (Soubannier
and Mcbride, 2009).
MITOCHONDRIA–ER COMMUNICATION AND METABOLISM
Like mitochondrion, ER is a highly dynamic organelle, under-
going constant shape remodeling, according to the cell require-
ments (Bravo-Sagua et al., 2013, 2014; English and Voeltz, 2013).
Furthermore, both organelles also have great intracellular motil-
ity, being able to change their distribution in the subcellular space
by moving along the cytoskeleton (Boldogh and Pon, 2007; Bola
and Allan, 2009). This motility is important for cell physiology,
because it determines the apposition between organelles and pref-
erential sites of signaling. Among other functions, ER is the main
intracellular Ca2+ reservoir. This ion is released to the cytoplasm
by two channels, the ryanodine receptor channel (RyR) and the
inositol trisphosphate receptor channel (InsP3R), and is returned
to the ER by the activity of the sarco/endoplasmic reticulum
Ca2+ ATPase (SERCA), a pump with high affinity and velocity
(Figure 2A) (Berridge et al., 2003).
Ca2+ has several roles within themitochondria, being required
for protein synthesis (Joyal et al., 1995), activation of several cit-
ric acid cycle dehydrogenases, oxidative phosphorylation, ATP
synthesis (Griffiths and Rutter, 2009), and it also enhances ROS
production (Dykens, 1994). The OMM, initially considered a per-
meable barrier, plays a critical role in mitochondrial Ca2+ uptake
(Csordas et al., 2002; Rapizzi et al., 2002). Ca2+ crosses this mem-
brane through the low affinity channel VDAC, which is regulated
by chaperones (Schwarzer et al., 2002), NADH (Lee et al., 1996)
and Bcl-2 family proteins (Vander Heiden et al., 2001). Ca2+
then crosses the IMM through the mitochondrial Ca2+ uniporter
(mCU), driven by the ψmt (Kirichok et al., 2004; Baughman
et al., 2011; De Stefani et al., 2011; Rizzuto et al., 2012). Ca2+
uptake intomitochondria requires high cytoplasmatic Ca2+ levels
in the surrounding area, concentrations achieved in the proxim-
ity of Ca2+ release sites located in the ER such as the InsP3R
(Figure 2B) (Csordas et al., 1999; Bravo-Sagua et al., 2013; Naon
and Scorrano, 2014).
We and others have shown that functional coupling between
these organelles promotes efficient Ca2+ entry intomitochondria,
resulting in a higher ψm and oxygen consumption (Figure 2B)
(Cardenas et al., 2010; Bravo et al., 2011). Increased mitochon-
drial Ca2+ concentration enhances oxidative phosphorylation,
through the activation of four mitochondrial dehydrogenases:
FAD-glycerol 3-phosphate dehydrogenase, pyruvate dehydroge-
nase, NAD-isocitrate dehydrogenase and oxoglutarate dehydro-
genase (Denton, 2009). In fact, blocking the entry of Ca2+ into
the mitochondria reduces oxidative phosphorylation and ener-
getically compromises the cell (Cardenas et al., 2010). Therefore,
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FIGURE 2 | Mitochondria-endoplasmic reticulum (ER) coupling. (A) Ca2+
release from the ER to the cytosol is mediated by two channels: ryanodine
receptor channel (RyR) and inositol trisphosphate receptor channel (InsP3R).
The sarcoendoplasmic reticulum Ca2+ transport ATPase (SERCA) is a pump
that transports Ca2+ from the cytoplasm into the ER. (B) Ca2+ transfer from
the ER to the mitochondria occurs within the mitochondria-associated
membranes (MAMs). Ca2+ is released from the ER to the mitochondria
through the InsP3R. Glucose-regulated protein 75 (GRP75) is a mitochondrial
chaperone that mediates the molecular interaction between InsP3R with the
voltage-dependent anion channel (VDAC). Ca2+ import across the OMM
occurs through VDAC. Ca2+ crosses the IMM through the mitochondrial Ca2+
uniporter channel (mCU) thanks to the considerable driving force represented
by the negative transmembrane potential and the high Ca2+ concentration
within the intermembrane space. Increased mitochondrial Ca2+ concentration
activates mitochondrial dehydrogenases and enhances the oxidative
phosphorylation, increasing oxygen consumption, ψm and ATP production.
several dehydrogenases of the tricarboxylic acid cycle increase
their activity in response to increments in mitochondrial Ca2+
content, which in turn depends on Ca2+ transients evoked by
muscle contraction. This allows an appropriate coupling between
contractile function and energy supply (Denton and Mccormack,
1990; Liu and O’Rourke, 2009).
The close contact zone between ER and mitochondria is called
Mitochondria-Associated Membrane (MAM) (Vance, 2014).
Several proteins compose and modulate this physical interac-
tion, such as calcium channels (InsP3R, VDAC), mitochondria-
shaping proteins (Mfn-2), chaperones (GRP75, sigma-1 receptor,
calnexin, oxidoreductases), sorting proteins (PACS-2), and other
enzymes [see reviews (Rowland and Voeltz, 2012; Bravo-Sagua
et al., 2013, 2014)]. The physical junction between the ER and
mitochondria relies on Mfn-2 and other proteins (De Brito and
Scorrano, 2008). In fact, genetic ablation of Mfn-2 results in dis-
rupted ER–mitochondria communication and causes a decrease
in both Ca2+ transfer and mitochondrial bioenergetics (Figure 3)
(Bravo et al., 2011; Bravo-Sagua et al., 2013).
Our group described changes in mitochondrial dynamics and
mitochondrial metabolism associated to cardiomyocyte apoptosis
(Parra et al., 2008), protection during heart ischemia/reperfusion
(Zepeda et al., 2014), cardiomyocyte hypertrophy (Pennanen
et al., 2014), and insulin resistance (Del Campo et al., 2014).
We also showed that insulin regulates cardiomyocyte metabolism
through the control of mitochondrial dynamics (Parra et al.,
2014). We also described that the association between two
organelles such as ER and mitochondria regulate mitochondrial
energetic function, especially as a novel adaptative mechanism
during ER stress (Bravo et al., 2011). Interestingly, when the asso-
ciation of both organelles is inhibited by a reduced expression of
the protein Mfn2, the metabolic changes are abrogated (Bravo
et al., 2011). On the other hand, it has been shown that ER–
mitochondria coupling also can induce apoptosis through the
connection of FIS-1 and Bap31 (an ER membrane protein). This
association interacts as a scaffold complex which facilitates cell
death signal transfer (Iwasawa et al., 2011).
MITOCHONDRIA, VSMC PROLIFERATION, AND APOPTOSIS
Mitochondrial metabolism is being recognized as a critical regula-
tor of cell growth and proliferation (Salabei and Hill, 2013). Cells
in active division have enhanced glycolysis and glutamine uti-
lization, which provide energy, NADPH, nucleotides, sugars, and
amino acids required for cell proliferation (Moncada et al., 2012).
In VSMCs, several growth factors, including PDGF-BB, increase
mitochondrial activity (Moncada et al., 2012). In pulmonary
artery hypertension (PAH) an increased proliferation rate of pul-
monary artery smooth muscle cells (PASMCs) is observed. These
cells have increased rates of glycolysis (Marsboom et al., 2012) and
showed mitochondrial fission (Bonnet et al., 2006; Marsboom
et al., 2012), suggesting a direct association between mito-
chondrial morphology and VSMC phenotypic change (Mitra,
2013). Salabei and Hill, proposed that the PDGF-BB-induced
dedifferentiation of VSMCs occurs via two separate processes,
i.e., proliferative responses driven by coupled transcriptional and
bioenergetic processes, and loss of contractile proteins largely
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FIGURE 3 | Effects of mitochondria and ER–mitochondrial coupling dysfunction. Unbalance in mitochondrial dynamics and ER–mitochondria uncoupling
can lead to VSMC phenotypic switching promoting vascular pathologies such as atherosclerosis, stenosis and pulmonary hypertension.
mediated by autophagy and downregulation of myofilament
genes (Salabei and Hill, 2013). Moreover, inhibition of DRP-1
using Mdivi-1, triggers mitochondrial fusion and prevented
PDGF-BB-induced upregulation of the cell cycle proteins prolif-
erating cell nuclear antigen (PCNA) and cyclin D1 (Salabei and
Hill, 2013).
VSMC proliferation and apoptosis can be also subject to
mitochondrial control through the action Mfn-2. In sponta-
neously hypertensive or atherosclerosis-prone rat VSMC, Mfn-2
levels were diminished (Chen et al., 2004), while overexpression
of Mfn2 reduced VSMC proliferation and sensitized to H2O2-
induced apoptosis (Guo et al., 2007a,b). We have shown that the
incretin glucagon-like peptide 1 (GLP-1) enhances the functional
coupling between ER and mitochondria in VSMC and promotes
a faster and higher increase of mitochondrial Ca2+ entry. This
enhanced coupling was associated with an increase in mitochon-
drial metabolism because inhibition of Ca2+ release from ER,
using the InsP3R blocker xestospongin B, or the blockade of
Ca2+ entry to the mitochondria, using RuRed, abolished GLP-
1-dependent increase of O2 consumption and ψm (Morales
et al., 2014). Therefore, it seems that communication between
mitochondria and the ER is an efficient mechanism for promot-
ing mitochondrial metabolism and regulating VSMC phenotype.
This enhancedmitochondria–ER coupling is due to an increase of
Mfn-2 through a protein kinase A (PKA)-dependent mechanism
(Morales et al., 2014). Guo et al. observed that forskolin increases
Mfn-2 expression in VSMC (Guo et al., 2007a). Similarly,
treatment of mouse Leydig tumor cells with 8Br-cAMP also
increases Mfn-2 mRNA and protein levels (Duarte et al., 2012).
Moreover, Mfn-2 has potent metabolic effects. In type 2 diabetes
patients, Mfn-2 mRNA and protein levels are diminished, and
these levels correlate with increased body mass index and dimin-
ished insulin sensitivity (Bach et al., 2005; Hernandez-Alvarez
et al., 2010). Furthermore, Mfn-2 depletion causes altered glu-
cose metabolism in vivo, as Mfn-2-KO mice developed glucose
intolerance, fasting hyperinsulinemia and altered insulin response
(Figure 3) (Sebastian et al., 2012).
Chen et al. showed that Mfn-2 diminishes in highly prolifer-
ative VSMC from atherosclerosis-prone or balloon-injured rats
and that Mfn-2 overexpression blocks proliferation of neointi-
mal VSMC after balloon injury (Chen et al., 2004). Moreover,
Mfn-2 overexpression also suppresses the proliferating effects of
oxidized-LDL in rabbit VSMC cultures. The induction of Mfn-
2 in vivo reduces PCNA positive cells at the neointimal and
medial layers from rabbit carotid arteries subjected to air-drying
damage (Guo et al., 2007b). These data correlate with the fact
that overexpression of Mfn-2 promotes mitochondrial-mediated
apoptosis in VSMC cultures, and that Mfn-2 is up-regulated and
necessary for H2O2-induced apoptosis albeit in a mitochondrial
fusion-independent mechanism (Guo et al., 2007a). This anti-
proliferative activity of Mfn-2 can be negatively regulated by PKA
as shown by the decreased PCNA positive cells and neointimal
hyperplasia after balloon injury on rats with overexpression of a
Mfn-2 S422A mutant form (a variant that cannot be phospho-
rylated on Ser422, the residue within the PKA-phosphorylation
consensus site) (Zhou et al., 2010). The authors suggest that
the anti-proliferative/pro-apoptotic activity of Mfn-2 might be a
result of down-regulation of the Raf/MAPK pathway or control
www.frontiersin.org December 2014 | Volume 2 | Article 72 | 5
Chiong et al. Mitochondrial metabolism and VSMC proliferation
over apoptotic-related proteins, given that cells overexpressing
Mfn-2 exhibit lower levels of ERK-1/2 and Akt in response to
certain hormones (Chen et al., 2004; Guo et al., 2007a,b) and an
increased Bcl-2/Bax ratio (Guo et al., 2007a).
During hypoxia most blood vessels relax but the pulmonary
arteries constrict, ultimately becoming occluded by excessive
PASMC proliferation, a condition that causes PAH. This is in
part because during hypoxia, mitochondria from PASMCs mod-
ifies ROS production, which diffuse to the plasma membrane
and regulate membrane voltage-dependent potassium channels
(Kv) and activate the hypoxia induced factor (HIF-1α) signaling
pathway, which is redox-sensitive (Michelakis et al., 2002). The
inhibition of Kv channels by mitochondrial ROS cause depolar-
ization, opening of voltage-gated Ca2+ channels, influx of Ca2+,
and vasoconstrictive response (Dromparis et al., 2010). However,
systemic VSMCs show totally opposite behavior of intracellular
Ca2+ in response to hypoxia. Furthermore, there are many differ-
ences between PASMC and systemic VSMC mitochondria, such
as decreased expression and function of the electron transporter
chain complexes I–III and increased expression of superoxide dis-
mutase (SOD). These differences are explained by differences in
baseline of mitochondrial ROS between PASMCs and VSMCs,
producing the opposite effect during hypoxia, contraction vs.
dilatation, respectively (Michelakis et al., 2002).
During the incipient PAH, the mitochondria from PASMC
become hyperpolarized and generate less ROS, indices of a
metabolic shift. This event is produced during normoxia and can
inhibit the Kv channel, which lead to an increase of intracellular
Ca2+ levels and generate vessel contraction (Archer et al., 2008).
In wild-type mice, these changes are accompanied by an excessive
PASMC proliferation, decrease in glucose oxidation and increased
glycolysis (Sutendra et al., 2010). When fatty acid oxidation is
abolished by deletion of the malonyl-coenzyme A decarboxylase
gene, thereby shifting the metabolic balance back to glucose oxi-
dation, the mice do not develop PAH and less or no PASMC
proliferation is observed (Sutendra et al., 2010). As mentioned
above, the shift away from glucose oxidation toward glycolysis and
fatty acid usage in the PASMCs during hypertension is accom-
panied by alterations in mitochondrial function (Sutendra et al.,
2010). Intracellular Ca2+ level increase and glucose oxidation
suppression activates transcriptional factors such as nuclear factor
of activated T-cells (NFAT) which promotes PASMC proliferation
in PAH (Bonnet et al., 2007; Sutendra et al., 2010). In PASMCs,
HIF-1α activation induces cell proliferation and also triggers
DRP-1-mediated mitochondrial fission. In vivo, cobalt activates
HIF-1α and induces PAH in rats. Co-administration of Mdivi-1,
restores mitochondrial fusion and reduces PAH (Marsboom et al.,
2012). Increased fission observed in PASMCs from PAH results
from DRP1 activation by increased cyclin B1/CDK1 activity and
accompanies cell cycle progression from G2 to mitosis. DRP-1
inhibition by Mdivi-1 slows proliferation by locking mitochon-
dria in fusion and inhibiting cell-cycle progression, causing G2/M
arrest (Marsboom et al., 2012).
When ER stress is induced by chronic normobaric hypoxia in
mice PASMCs, mitochondrial Ca2+, 2-oxoglutarate content and
pyruvate dehydrogenase activity were decreased, depicting mito-
chondrial malfunction under these conditions (Sutendra et al.,
2011). Sutendra et al. show that the Nogo-B protein, member of
the reticulon family, which is critical in the regulation of tubu-
lar ER structure, is induced by hypoxia only in lung vessels,
where it disrupts the contacts between the ER and the mito-
chondria (Sutendra et al., 2011). This alteration disrupts essential
mitochondrial functions, causing overgrowth of PASMCs and
ultimately PAH. Moreover, Nogo controls the ER shape and
inhibits apoptosis during vascular remodeling (Sutendra et al.,
2011).
MITOCHONDRIAL DYSFUNCTION IN ATHEROSCLEROSIS
Damage to the vascular environment by oxidative stress plays a
major role in the pathogenesis of atherosclerosis. Under normal
conditions, ROS production is controlled by mitochondria and
ROS levels are sensed by enzymatic systems and cellular mech-
anisms. Alteration in ROS production is frequently observed in
atherosclerosis. Oxidative stress results in lipid peroxidation and
damage of mitochondrial components, including mitochondrial
DNA (mtDNA), leading to mitochondrial dysfunction. mtDNA is
also affected by mitochondrial fission process. Cleavage of OPA-1
leads to mtDNA loss, respiratory chain deficiency and mito-
chondrial ROS increase (Duvezin-Caubet et al., 2006; Finsterer,
2007; Parone et al., 2008). ROS increase activates poly(ADP-
ribose) polymerase 1 (PARP-1), enzyme involved in chromatin
structure modulation and DNA repair, which increases VSMC
and endothelial cell death, facilitating atherosclerosis progression
(Virag, 2005). Alteration in mitochondrial anti-oxidant enzyme
levels, such as manganese superoxide dismutase (MnSOD),
increases mtDNA damage in ApoE−/− mice (Ballinger et al.,
2002). Furthermore, the extent of mitochondrial, but not nuclear,
DNA damage correlates with the development of atherosclerotic
VSMC lesions in mice and human aortic tissues (Ballinger et al.,
2002). Mitochondrial stress, induced by the mtDNA replication
inhibitor, dideoxycytidine, promotes VSMC migration, but not
proliferation, suggesting that malfunction of mitochondria may
be involved in the plaque stabilization in late-stage atheroscle-
rosis (Ahn et al., 2010). Plaque stabilization is accompanied
by increase in VSMC and macrophage apoptosis which pro-
motes induction of pro-coagulation and plaque rupture (Clarke
et al., 2006). Also, VSMC functionality depends onmitochondrial
genes transcription. VSMC-specific ablation of the mitochon-
drial transcription factor Tfam results in a diminished contractile
response of mesenteric artery rings to phenylephrine (Jawien
et al., 2008). Prevention of the upregulation of this transcrip-
tion factor, observed in carotid artery from rats subjected to
balloon injury, might prevent intimal thickening in this type
of damaged-artery model (Yoshida et al., 2005). On the other
hand, mitochondrial dysfunction in macrophages (changes in
ATP production, ψmt, and mtDNA damage) alters cholesterol
trafficking betweenmitochondrial membranes facilitating choles-
terol accumulation at the interface mitochondrial membrane–ER.
This accumulation facilitates interaction between cholesterol and
CYP27A1 due to the permeability transition pore (PTP) aperture,
generating 27-oxygenated derivatives of cholesterol and accumu-
lation within vascular cells (Allen et al., 2013). These results,
among others, suggest that mitochondrial dysfunction is a possi-
ble hallmark of vascular diseases. Intervention and modulation of
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these mechanisms will be useful in the treatment and prevention
of atherosclerosis progression.
CONCLUDING REMARKS
VSMC proliferation plays a key role in atherogenesis and resteno-
sis. Mitochondrial dysfunction is a metabolic feature that con-
trol VSMC phenotype. Targeting of mitochondrial function
with dichloroacetate (Mcmurtry et al., 2004) or trimetazidine
(Sutendra et al., 2010) has been successfully used to avoid
VSMC or PASMC proliferation in animal models. However, only
rapamycin has been tested in human, specifically in drug eluting
stents to avoid restenosis (Kang et al., 2011; Testa et al., 2011).
Major translational challenges remain in this exciting area, but
patients with vascular disease are likely to benefit from these
efforts.
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